Pages that link to "Q35781605"

The following pages link to Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes (Q35781605):

Displaying 25 items.

• Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia (Q36583644) (← links)
• TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes (Q37392696) (← links)
• Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel (Q37624593) (← links)
• Mutation profiling of 19 candidate genes in acute myeloid leukemia suggests significance of DNMT3A mutations (Q37688148) (← links)
• Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate? (Q38540862) (← links)
• ASXL1 mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcomes and survival (Q38777486) (← links)
• The Role of Additional Sex Combs-Like Proteins in Cancer (Q38928350) (← links)
• Mutations in AML: prognostic and therapeutic implications (Q39027793) (← links)
• The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice. (Q39363419) (← links)
• Screening of mutations in the additional sex combs like 1, transcriptional regulator, tumor protein p53, and KRAS proto-oncogene, GTPase/NRAS proto-oncogene, GTPase genes of patients with myelodysplastic syndrome (Q41530601) (← links)
• Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens (Q47133143) (← links)
• High expression of ABCG2 induced by EZH2 disruption has pivotal roles in MDS pathogenesis (Q48106388) (← links)
• Time to revise the revised-International Prognostic Scoring System? (Q49043958) (← links)
• Acute myeloid leukemia in a father and son with a germline mutation of ASXL1. (Q49873907) (← links)
• Association of mutations with morphologic dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities (Q50078399) (← links)
• The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications. (Q52777531) (← links)
• Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing. (Q53412376) (← links)
• Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care (Q57058970) (← links)
• Molecular landscape and targeted therapy of acute myeloid leukemia (Q59130314) (← links)
• The Progress of Next Generation Sequencing in the Assessment of Myeloid Malignancies (Q64085749) (← links)
• ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype (Q90678434) (← links)
• A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60-year-old acute myeloid leukemia patients with myelodysplasia syndrome features (Q92019863) (← links)
• New drugs creating new challenges in acute myeloid leukemia (Q92301124) (← links)
• Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia (Q92987302) (← links)
• Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC) (Q99631429) (← links)